Last reviewed · How we verify
perindopril, indapamide , amlodipine
At a glance
| Generic name | perindopril, indapamide , amlodipine |
|---|---|
| Also known as | Procaptan, Indapamide, Norvasc |
| Sponsor | University of Roma La Sapienza |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Patients With DIABETES Mellitus (OPTIMAL-DIABETES) (NA)
- OBPM_Meds2023: Multicentric Prospective Clinical Study to Evaluate the Aktiia Optical Blood Pressure Monitoring (OBPM) Device Compared to Standard Home Blood Pressure Monitoring (HBPM) in Hypertensive Patients When Blood Pressure Lowering Medications Intake (NA)
- Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) (NA)
- Evaluation of the Antihypertensive effectIveness, Tolerability, and Adherence With Amlodipine/ Indapamide/ Perindopril Triple Single-pill Combination in Hypertensive Patients Without Concomitant Antihypertensive Therapy (TRIPTYCH)
- Treatment Optimisation for Blood Pressure With Single-Pill Combinations in India (PHASE4)
- Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertension (PHASE3)
- Optimal Medical Treatment of Difficult-to-treat Hypertension (PHASE4)
- Optimal Blood Pressure for the prevenTIon of Major vAscuLar Events in Stroke Patients (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: